1 | Visilizumab | [1] Visilizumab Visilizumab | [1] Visilizumab
Visilizumab
💬 | [3] CD3D CD3D, CD3E, CD3G 💬 | [11] Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | [2] 96 96, 97 💬 |
2 | Visilizumab (HuM291 | [1] Visilizumab Visilizumab | [1] Visilizumab
Visilizumab
💬 | [3] CD3D CD3D, CD3E, CD3G 💬 | [11] Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | [1] 97 97 💬 |
3 | Visilizumab (Nuvion) | [1] Visilizumab Visilizumab | [1] Visilizumab
Visilizumab
💬 | [3] CD3D CD3D, CD3E, CD3G 💬 | [11] Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | [1] 97 97 💬 |
4 | Visilizumab (Nuvion® | [1] Visilizumab Visilizumab | [1] Visilizumab
Visilizumab
💬 | [3] CD3D CD3D, CD3E, CD3G 💬 | [11] Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | [1] 97 97 💬 |